DED is prompted when the amount or high quality of tears fails to maintain the floor of the eye correctly lubricated, and related to signs resembling irritation. Increased display screen time and different way of life modifications, is cited as one of many essential causes for DED.
CEQUA – cyclosporine ophthalmic answer 0.09%, is the primary dry eye remedy obtainable in India that’s delivered utilizing nanomicellar (NCELL) expertise that gives higher supply over cyclosporine emulsion 0.05%
Sun Pharma launched the therapy in the US market in October 2019, following intensive scientific research. The specialty therapy has been one of many main income contributors for Sun Pharma’s specialty drug enterprise.
“Current remedy choices for dry eye disease have limitations and therefore a robust unmet want exists in this house,” stated Kirti Ganorkar, CEO, India Business at Sun Pharma.
“We are excited to introduce CEQUA as a brand new remedy choice for DED in India. This is a vital milestone for Sun Pharma as we deliver one among our key world specialty merchandise to India,” Ganorkar stated.
“Global scientific trials have proven that CEQUA offers quicker outcomes and is snug to a lot of the sufferers proper from the beginning of remedy,” stated Dr. Rohit Shetty, vice chairman of Narayana Nethralaya Eye Institute,The prevalence of DED in India is larger than the worldwide prevalence and a big regional research pegged India’s prevalence at 32%, of which 90% had been affected with average/extreme DED. It is projected that the prevalence of DED is prone to enhance to 45% in India’s city inhabitants by 2030.
